Company
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
LS CancerDiag has developed DiagMMR®, a unique predictive diagnostic test to detect Lynch syndrome (LS). We provide easily interpretable and highly accurate results even before cancers develop, enabling preventive and personalized care.
Helsinki, Uusimaa, Finland
Send a message
Anglais
Anglais
LS CancerDiag is committed to reducing cancer mortality rates with a diagnostic method that detects an inherited cancer-causing condition prior to cancer.
DiagMMR® is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers. While current LS diagnosis relies on tumor studies, the quantitative DiagMMR® method allows carrier diagnosis based on a...
LS CancerDiag is committed to reducing cancer mortality rates with a diagnostic method that detects an inherited cancer-causing condition prior to cancer.
DiagMMR® is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers. While current LS diagnosis relies on tumor studies, the quantitative DiagMMR® method allows carrier diagnosis based on a non-invasive tissue sample before the person has developed a cancer, without the knowledge and details of an inherited mutation.
2
Followers
1
Like
Start in Aug 2013
Aug 2013
LS CancerDiag is founded as a Spin-off from the University of Helsinki.
2014-2018
Patents filed and granted in all major markets (incl. EU, USA, China, Russia, Japan)
2016
LS CancerDiag joins Startup Health.
2018
Optimization and validation is completed.
2019
CE-mark obtained as IVD MD. Distribution agreements signed in Finland.
to be continued ...